Epidermal growth factor receptor (EGFR) polymorphisms and breast cancer among Hispanic and non-Hispanic white women: The Breast Cancer Health Disparities Study

Avonne Connor, Richard N. Baumgartner, Kathy B. Baumgartner, Christina M. Pinkston, Esther M. John, Gabriela Torres-Mejía, Lisa M. Hines, Anna R. Giuliano, Roger K. Wolff, Martha L. Slattery

Research output: Contribution to journalArticle

Abstract

The epidermal growth factor receptor (EGFR), a member of the ErbB family of receptor tyrosine kinases, functions in cellular processes essential to the development of cancer. Overexpression of EGFR in primary breast tumors has been linked with poor prognosis. We investigated the associations between 34 EGFR tagging SNPs and breast cancer risk and breast cancer-specific mortality in 4,703 Hispanic and 3,030 non-Hispanic white women from the Breast Cancer Health Disparities Study. We evaluated associations with risk of breast cancer defined by estrogen/progesterone receptor (ER/PR) tumor phenotype. Only one association remained statistically significant after adjusting for multiple comparisons. Rs2075112GA/AA was associated with reduced risk for ER-/PR+ tumor phenotype (odds ratio (OR), 0.34; 95% confidence interval (CI) 0.18-0.63, p adj=0.01). All additional results were significant prior to adjustment for multiple comparisons. Two of the EGFR polymorphisms were associated with breast cancer risk in the overall study population (rs11770531TT: OR, 0.56, 95% CI 0.37-0.84; and rs2293348AA: OR, 1.20, 95% CI 1.04-1.38) and two polymorphisms were associated with risk among Hispanics: rs6954351AA: OR, 2.50, 95% CI 1.32-4.76; and rs845558GA/AA: OR, 1.15, 95% CI 1.01-1.30. With regard to breast cancer-specific mortality, we found positive associations with rs6978771TT hazard ratio (HR), 1.68; 95% CI 1.11-2.56; rs9642391CC HR, 1.64; 95% CI 1.04-2.58; rs4947979AG/GG HR, 1.36; 95% CI 1.03-1.79; and rs845552GG HR, 1.62; 95% CI 1.05-2.49. Our findings provide additional insight for the role of EGFR in breast cancer development and prognosis. Further research is needed to elucidate EGFR's contribution to ethnic disparities in breast cancer.

Original languageEnglish (US)
Pages (from-to)235-249
Number of pages15
JournalInternational Journal of Molecular Epidemiology and Genetics
Volume4
Issue number4
StatePublished - 2013
Externally publishedYes

Fingerprint

Hispanic Americans
Epidermal Growth Factor Receptor
Breast Neoplasms
Confidence Intervals
Health
Odds Ratio
Phenotype
Neoplasms
Mortality
Progesterone Receptors
Estrogen Receptors
Protein-Tyrosine Kinases
Single Nucleotide Polymorphism

Keywords

  • Breast cancer
  • Epidermal growth factor receptor
  • Hispanic
  • Polymorphisms
  • Tumor phenotype

ASJC Scopus subject areas

  • Epidemiology
  • Genetics(clinical)
  • Genetics

Cite this

Epidermal growth factor receptor (EGFR) polymorphisms and breast cancer among Hispanic and non-Hispanic white women : The Breast Cancer Health Disparities Study. / Connor, Avonne; Baumgartner, Richard N.; Baumgartner, Kathy B.; Pinkston, Christina M.; John, Esther M.; Torres-Mejía, Gabriela; Hines, Lisa M.; Giuliano, Anna R.; Wolff, Roger K.; Slattery, Martha L.

In: International Journal of Molecular Epidemiology and Genetics, Vol. 4, No. 4, 2013, p. 235-249.

Research output: Contribution to journalArticle

Connor, A, Baumgartner, RN, Baumgartner, KB, Pinkston, CM, John, EM, Torres-Mejía, G, Hines, LM, Giuliano, AR, Wolff, RK & Slattery, ML 2013, 'Epidermal growth factor receptor (EGFR) polymorphisms and breast cancer among Hispanic and non-Hispanic white women: The Breast Cancer Health Disparities Study', International Journal of Molecular Epidemiology and Genetics, vol. 4, no. 4, pp. 235-249.
Connor, Avonne ; Baumgartner, Richard N. ; Baumgartner, Kathy B. ; Pinkston, Christina M. ; John, Esther M. ; Torres-Mejía, Gabriela ; Hines, Lisa M. ; Giuliano, Anna R. ; Wolff, Roger K. ; Slattery, Martha L. / Epidermal growth factor receptor (EGFR) polymorphisms and breast cancer among Hispanic and non-Hispanic white women : The Breast Cancer Health Disparities Study. In: International Journal of Molecular Epidemiology and Genetics. 2013 ; Vol. 4, No. 4. pp. 235-249.
@article{fa2c072b26ce401cafa6a0b651dc8337,
title = "Epidermal growth factor receptor (EGFR) polymorphisms and breast cancer among Hispanic and non-Hispanic white women: The Breast Cancer Health Disparities Study",
abstract = "The epidermal growth factor receptor (EGFR), a member of the ErbB family of receptor tyrosine kinases, functions in cellular processes essential to the development of cancer. Overexpression of EGFR in primary breast tumors has been linked with poor prognosis. We investigated the associations between 34 EGFR tagging SNPs and breast cancer risk and breast cancer-specific mortality in 4,703 Hispanic and 3,030 non-Hispanic white women from the Breast Cancer Health Disparities Study. We evaluated associations with risk of breast cancer defined by estrogen/progesterone receptor (ER/PR) tumor phenotype. Only one association remained statistically significant after adjusting for multiple comparisons. Rs2075112GA/AA was associated with reduced risk for ER-/PR+ tumor phenotype (odds ratio (OR), 0.34; 95{\%} confidence interval (CI) 0.18-0.63, p adj=0.01). All additional results were significant prior to adjustment for multiple comparisons. Two of the EGFR polymorphisms were associated with breast cancer risk in the overall study population (rs11770531TT: OR, 0.56, 95{\%} CI 0.37-0.84; and rs2293348AA: OR, 1.20, 95{\%} CI 1.04-1.38) and two polymorphisms were associated with risk among Hispanics: rs6954351AA: OR, 2.50, 95{\%} CI 1.32-4.76; and rs845558GA/AA: OR, 1.15, 95{\%} CI 1.01-1.30. With regard to breast cancer-specific mortality, we found positive associations with rs6978771TT hazard ratio (HR), 1.68; 95{\%} CI 1.11-2.56; rs9642391CC HR, 1.64; 95{\%} CI 1.04-2.58; rs4947979AG/GG HR, 1.36; 95{\%} CI 1.03-1.79; and rs845552GG HR, 1.62; 95{\%} CI 1.05-2.49. Our findings provide additional insight for the role of EGFR in breast cancer development and prognosis. Further research is needed to elucidate EGFR's contribution to ethnic disparities in breast cancer.",
keywords = "Breast cancer, Epidermal growth factor receptor, Hispanic, Polymorphisms, Tumor phenotype",
author = "Avonne Connor and Baumgartner, {Richard N.} and Baumgartner, {Kathy B.} and Pinkston, {Christina M.} and John, {Esther M.} and Gabriela Torres-Mej{\'i}a and Hines, {Lisa M.} and Giuliano, {Anna R.} and Wolff, {Roger K.} and Slattery, {Martha L.}",
year = "2013",
language = "English (US)",
volume = "4",
pages = "235--249",
journal = "International Journal of Molecular Epidemiology and Genetics",
issn = "1948-1756",
publisher = "e-Century Publishing Corporation",
number = "4",

}

TY - JOUR

T1 - Epidermal growth factor receptor (EGFR) polymorphisms and breast cancer among Hispanic and non-Hispanic white women

T2 - The Breast Cancer Health Disparities Study

AU - Connor, Avonne

AU - Baumgartner, Richard N.

AU - Baumgartner, Kathy B.

AU - Pinkston, Christina M.

AU - John, Esther M.

AU - Torres-Mejía, Gabriela

AU - Hines, Lisa M.

AU - Giuliano, Anna R.

AU - Wolff, Roger K.

AU - Slattery, Martha L.

PY - 2013

Y1 - 2013

N2 - The epidermal growth factor receptor (EGFR), a member of the ErbB family of receptor tyrosine kinases, functions in cellular processes essential to the development of cancer. Overexpression of EGFR in primary breast tumors has been linked with poor prognosis. We investigated the associations between 34 EGFR tagging SNPs and breast cancer risk and breast cancer-specific mortality in 4,703 Hispanic and 3,030 non-Hispanic white women from the Breast Cancer Health Disparities Study. We evaluated associations with risk of breast cancer defined by estrogen/progesterone receptor (ER/PR) tumor phenotype. Only one association remained statistically significant after adjusting for multiple comparisons. Rs2075112GA/AA was associated with reduced risk for ER-/PR+ tumor phenotype (odds ratio (OR), 0.34; 95% confidence interval (CI) 0.18-0.63, p adj=0.01). All additional results were significant prior to adjustment for multiple comparisons. Two of the EGFR polymorphisms were associated with breast cancer risk in the overall study population (rs11770531TT: OR, 0.56, 95% CI 0.37-0.84; and rs2293348AA: OR, 1.20, 95% CI 1.04-1.38) and two polymorphisms were associated with risk among Hispanics: rs6954351AA: OR, 2.50, 95% CI 1.32-4.76; and rs845558GA/AA: OR, 1.15, 95% CI 1.01-1.30. With regard to breast cancer-specific mortality, we found positive associations with rs6978771TT hazard ratio (HR), 1.68; 95% CI 1.11-2.56; rs9642391CC HR, 1.64; 95% CI 1.04-2.58; rs4947979AG/GG HR, 1.36; 95% CI 1.03-1.79; and rs845552GG HR, 1.62; 95% CI 1.05-2.49. Our findings provide additional insight for the role of EGFR in breast cancer development and prognosis. Further research is needed to elucidate EGFR's contribution to ethnic disparities in breast cancer.

AB - The epidermal growth factor receptor (EGFR), a member of the ErbB family of receptor tyrosine kinases, functions in cellular processes essential to the development of cancer. Overexpression of EGFR in primary breast tumors has been linked with poor prognosis. We investigated the associations between 34 EGFR tagging SNPs and breast cancer risk and breast cancer-specific mortality in 4,703 Hispanic and 3,030 non-Hispanic white women from the Breast Cancer Health Disparities Study. We evaluated associations with risk of breast cancer defined by estrogen/progesterone receptor (ER/PR) tumor phenotype. Only one association remained statistically significant after adjusting for multiple comparisons. Rs2075112GA/AA was associated with reduced risk for ER-/PR+ tumor phenotype (odds ratio (OR), 0.34; 95% confidence interval (CI) 0.18-0.63, p adj=0.01). All additional results were significant prior to adjustment for multiple comparisons. Two of the EGFR polymorphisms were associated with breast cancer risk in the overall study population (rs11770531TT: OR, 0.56, 95% CI 0.37-0.84; and rs2293348AA: OR, 1.20, 95% CI 1.04-1.38) and two polymorphisms were associated with risk among Hispanics: rs6954351AA: OR, 2.50, 95% CI 1.32-4.76; and rs845558GA/AA: OR, 1.15, 95% CI 1.01-1.30. With regard to breast cancer-specific mortality, we found positive associations with rs6978771TT hazard ratio (HR), 1.68; 95% CI 1.11-2.56; rs9642391CC HR, 1.64; 95% CI 1.04-2.58; rs4947979AG/GG HR, 1.36; 95% CI 1.03-1.79; and rs845552GG HR, 1.62; 95% CI 1.05-2.49. Our findings provide additional insight for the role of EGFR in breast cancer development and prognosis. Further research is needed to elucidate EGFR's contribution to ethnic disparities in breast cancer.

KW - Breast cancer

KW - Epidermal growth factor receptor

KW - Hispanic

KW - Polymorphisms

KW - Tumor phenotype

UR - http://www.scopus.com/inward/record.url?scp=84889650961&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84889650961&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84889650961

VL - 4

SP - 235

EP - 249

JO - International Journal of Molecular Epidemiology and Genetics

JF - International Journal of Molecular Epidemiology and Genetics

SN - 1948-1756

IS - 4

ER -